Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ipsen
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient must give written (personally signed and dated) informed consent before completing any study-related procedure, which means any assessment or evaluation that would not have formed part of the normal medical care of the patient
Patient must be 18 years old or over
Patient must have a histologically-confirmed diagnosis of locally advanced or metastatic prostate cancer or presenting a relapse after curative treatment which is amenable to androgen deprivation therapy
Patient must have an estimated survival time of greater than 8 months according to the investigator's assessment
You may not be if
Patient at risk of a serious complication in the case of tumour flare (vertebral metastases threatening spinal cord compression or with significant obstructive uropathy)
Patient who underwent a previous surgical castration
Prostate cancer therapy within 2 months of baseline visit
Patient with testosterone level below 150 ng/dL at screening
Clareo Health | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer
